Prosecution Insights
Last updated: April 19, 2026
Application No. 18/412,997

CYCLOSILAZANE PRECURSORS AND RELATED METHODS

Non-Final OA §102§112
Filed
Jan 15, 2024
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Entegris Inc.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
65%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
1407 granted / 1741 resolved
+20.8% vs TC avg
Minimal -16% lift
Without
With
+-16.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
54 currently pending
Career history
1795
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
15.2%
-24.8% vs TC avg
§102
21.0%
-19.0% vs TC avg
§112
42.6%
+2.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1741 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-20 are pending in the application. Claim Rejections - 35 USC § 112 3. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9 and 16-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In independent claims 1 and 16, the term - - A precursor comprising - - - is vague and indefinite since it is not clear whether precursor is represented by this compound (5-membered ring containing 2N and 3Si atoms) or some other larger compound of unknown structure having this compound embedded somewhere. Claim 2 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 3 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 4 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 5 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 7 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 8 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 9 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 3-6, 8-10 and 12-15 are rejected under 35 U.S.C. 102(a) (1) as being anticipated by Wannagat (Zeitsch. Fuer. Anorgan. and Allgem. Chem.). Wannagat discloses silicon-nitrogen compounds and a process for preparing these compounds. The compounds B5 and B6 and a process for preparing these compounds (see page 49) disclosed by Wannagat anticipate the instant claims when variables R1-R5 represent methyl group or R1, R2, R4 and R5 represents methyl group and variable R3 represents propyl group in the instant compounds. Claims 1, 3-4 and 8 are rejected under 35 U.S.C. 102(a) (1) as being anticipated by compound with RN 133823-16-2. The compound with RN 133823-16-2 was entered in STN on May 17, 1991 and therefore, anticipates the instant claims when variable R3 represents H and variables R1, R2, R4 and R5 represent methyl group in the instant claims. It is of note that these claims are directed to product by process and therefore, process is irrelevant. Allowable Subject Matter Claims 11 and 18-20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jan 15, 2024
Application Filed
Feb 22, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594251
BENZALKONIUM CHLORIDE FORUSE IN TREATING CONJUNCTIVITIS AND/OR COVID-19
2y 5m to grant Granted Apr 07, 2026
Patent 12583829
SALT OF BENZOTHIAZOLE COMPOUND, AND CRYSTAL FORM AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12581852
COMPOUND, LUMINESCENT MATERIAL, DELAYED FLUORESCENT MATERIAL, AND ORGANIC OPTICAL DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12569479
BUPROPION AS A MODULATOR OF DRUG ACTIVITY
2y 5m to grant Granted Mar 10, 2026
Patent 12564586
KAPPA OPIOD RECEPTOR ANTAGONISTS FOR TREATING PAIN-RELATED SLEEP DISORDERS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
65%
With Interview (-16.0%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 1741 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month